Author

Michele Schmidt

Observed names: M Schmidt, M. Schmidt

Institution: Mayo Clinic

Observed institutions: Mayo Clinic, Philipps University of Marburg, Heidelberg University, Hanusch Hospital, Celgene (United States), University of Duisburg-Essen, University of Lübeck

OpenAlex ID: A5085998264

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

2006 · Alan List, Gordon Dewald, et al. · New England Journal of Medicine · 1,324

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

2007 · Azra Raza, James A. Reeves, et al. · Blood · 425

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

1984 · G. Brittinger, H. Bartels, et al. · Hematological Oncology · 207

Lymphoplasmacytic/lymphoplasmacytoid lymphoma: A clinical entity distinct from chronic lymphocytic leukaemia?

1981 · R. Heinz, A. Stacher, et al. · Annals of Hematology · 36

Principles and present status of a prospective multicenter study on the clinical relevance of the kiel classification

1981 · G. Brittinger, U. Schmalhorst, et al. · Annals of Hematology · 34

CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study

1989 · H Köppler, KH Pflüger, et al. · British Journal of Cancer · 30

Clinical and prognostic heterogeneity of non-hodgkin lymphomas of high-grade malignancy

1981 · U. Schmalhorst, H. Bartels, et al. · Annals of Hematology · 19

No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer

2009 · Ellen L Goode, Csilla Szabo, et al. · BMC Cancer · 17

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

2006 · Alan F. List, Gordon W. Dewald, et al. · Blood · 17

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

2006 · Azra Raza, James E. Reeves, et al. · Blood · 13

Germinal center cell lymphomas: Prognostic significance of their histopathological differentiation

1981 · E. K�nig, H. Bartels, et al. · Annals of Hematology · 12

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

2007 · Alan F. List, Jeffrey E. Lancet, et al. · Blood · 10

Venous thromboembolism in patients with myelodysplastic syndrome treated with lenalidomide: Incidence and risk factors

2008 · N. A. Brandenburg, L. Weiss, et al. · Journal of Clinical Oncology · 6

Erythroid response to lenalidomide (LEN) + recombinant erythropoietin (EPO) and endogenous serum EPO concentration in MDS cytokine-failures

2008 · J. E. Lancet, J. Yu, et al. · Journal of Clinical Oncology · 2

Multizentrische Studie zur Behandlung hochmaligner Non-Hodgkin-Lymphome mit Polychemotherapie (CHOPV) und Bestrahlung

2009 · H. Köppler, K.H. Pflüger, et al. · Onkologie · 1

[Prospective study on remission induction and maintenance in malignant lymphomas].

1974 · H Malchow, L Buchelt, et al. · PubMed

[What is reliable in the therapy of hematologic diseases? II. Anemias, myeloproliferative diseases, panmyelopathy and agranulocytosis].

1970 · C P Sodomann, H Malchow, et al. · PubMed

Works count: 17

Citation count: 2,153

H-index: 11

I10-index: 12